Effect of add-on empagliflozin on arterial stiffness in patients with type 2 diabetes and cardiovascular disease: an analysis from a placebo-controlled EMBLEM trial

DOI Web Site 参考文献20件
  • Tanaka Atsushi
    Department of Cardiovascular Medicine, Saga University
  • Teragawa Hiroki
    Department of Cardiovascular Medicine, JR Hiroshima Hospital
  • Takamura Toshinari
    Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences
  • Maruhashi Tatsuya
    Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University
  • Yamaoka-Tojo Minako
    Department of Cardiovascular Medicine, Kitasato University School of Medicine
  • Ako Junya
    Department of Cardiovascular Medicine, Kitasato University School of Medicine
  • Yufu Kunio
    Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine
  • Takahashi Naohiko
    Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine
  • Tomiyama Hirofumi
    Department of Cardiology, Tokyo Medical University
  • Higashi Yukihito
    Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University
  • Node Koichi
    Department of Cardiovascular Medicine, Saga University
  • on behalf of the EMBLEM Investigators

この論文をさがす

抄録

<p>Background: Although sodium glucose co-transporter 2 (SGLT2) inhibition has been proven to have preventive and therapeutic effects on heart failure, its clinical effect on arterial stiffness remains controversial. Herein, we sought to assess the effect of add-on empagliflozin treatment on arterial stiffness, assessed as brachial-ankle pulse wave velocity (baPWV), in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD).</p><p>Methods and Results: This was a prespecified secondary analysis of the effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: multi-center placebo-controlled double-blind randomized (EMBLEM) trial (UMIN000024502), which was designed primarily to evaluate the effect of empagliflozin, relative to placebo, on endothelial function in patients with T2D and CVD. The present analysis compared the changes in baPWV from baseline to week 24 between empagliflozin (10 mg once daily, n = 13) and placebo (n = 13) groups. Absolute change from baseline to week 24 in baPWV was 54.9 ± 123.9 cm/s in the empagliflozin group and 43.7 ± 166.4 cm/s in the placebo group (mean group difference, 11.2 cm/s [95% confidence interval, -108.1 to 130.5], P = 0.848).</p><p>Conclusions: Add-on empagliflozin treatment did not affect baPWV in EMBLEM trial participants.</p><p>Trial registration: University Medical Information Network Clinical Trial Registry, number 000024502</p>

収録刊行物

  • Vascular Failure

    Vascular Failure 6 (1), 1-7, 2022-12-25

    一般社団法人 日本血管不全学会

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ